Clinical Trials Browser

Phase 2 × Withdrawn × enasidenib × Clear all

NCT03881735 2021-03-10

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

Phase 2 Withdrawn

Other hematologic neoplasm

Leukemia, Myeloid, Acute